Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder

CNS Drugs

Volumn 26, Issue 5, 2012, Pages 403-420

  Gigante, Alexandre Duarte ^a   Lafer, Beny ^a   Yatham, Lakshmi N ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antipsychotics; Bipolar disorders; Bipolar I disorders; Bipolar II disorders; Controlled release drugs; Flupentixol; Fluphenazine; Haloperidol; Olanzapine; Paliperidone; Risperidone

Indexed keywords

AMISULPRIDE; CHOLESTEROL; EMBONIC ACID; FLUPENTIXOL; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PALMITIC ACID; PIPOTIAZINE; PROCYCLIDINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZUCLOPENTHIXOL;

ACUTE DISEASE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CASE STUDY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERTENSION; HYPOKINESIA; INJECTION SITE PAIN; INSOMNIA; MANIA; MEDICAL RECORD REVIEW; MUSCLE RIGIDITY; NAUSEA; OPEN STUDY; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; DRUG APPROVAL; HUMANS; INJECTIONS; MEDICATION ADHERENCE; RISPERIDONE;

EID: 84859961570     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11631310-000000000-00000     Document Type: Review

References (43)

1. Merikangas K, Akiskal H, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64 (5): 543-52 (Pubitemid 46718287)
2. Tohen M, Hennen J, Zarate CJ, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000;157 (2): 220-8 (Pubitemid 30080901)
3. MacQueen G, Young L, Joffe R. A review of psychosocial outcome in patients with bipolar disorder. Acta Psychiatr Scand 2001;103 (3): 163-70 (Pubitemid 32154347)
4. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007;(434): 17-26 (Pubitemid 47231065)
5. Kauer-Sant'Anna M, Bond DJ, Lam RW, et al. Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. Compr Psychiatry 2009 Jan-Feb;50 (1): 1-8
6. Rosa A, Reinares M, Michalak E, et al. Functional impairment and disability across mood states in bipolar disorder. Value Health 2010 Dec;13 (8): 984-8
7. Miklowitz DJ. Functional impairment, stress, and psychosocial intervention in bipolar disorder. Curr Psychiatry Rep 2011 Dec;13 (6): 504-12
8. Rosa AR, Reinares M, Franco C, et al. Clinical predictors of functional outcome of bipolar patients in remission. Bipolar Disord 2009;11 (4): 401-9
9. López-Jaramillo C, Lopera-Vaáquez J, Gallo A, et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. BipolarDisord 2010Aug;12 (5): 557-67
10. Hong J, Reed C, Novick D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 2011;190 (1): 110-4
11. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002 Mar;105 (3): 164-72 (Pubitemid 34280688)
12. Bates JA, Whitehead R, Bolge SC, et al. Correlates of medication adherence among patients with bipolar disorder: results of the Bipolar Evaluation of Satisfaction and Tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry 2010;12 (5): PCC.09m00883
13. Gonzälez-Pinto A, Reed C, Novick D, et al. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 2010 Nov;43 (7): 263-70
14. Suppes T, Baldessarini RJ, FaeddaGL, et al.Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991 Dec;48 (12): 1082-8
15. Müller-Oerlinghausen B, Müser-Causemann B, Volk J. Suicides and parasuicides in a high-risk patient group on and off lithium long-term medication. J Affect Disord 1992 Aug;25 (4): 261-9
16. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002 Nov;159 (11): 1927-9 (Pubitemid 35283261)
17. Cavanagh J, Smyth R, Goodwin GM. Relapse into mania or depression following lithium discontinuation: a 7-year follow-up. Acta Psychiatr Scand 2004 Feb;109 (2): 91-5 (Pubitemid 38186819)
18. Angst J, Angst F, Gerber-Werder R, et al. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005;9 (3): 279-300 (Pubitemid 40977549)
19. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to longterm lithium treatment. Bipolar Disord 2006 Oct;8 (5 Pt 2): 618-24 (Pubitemid 44567143)
20. Perlis RH, Ostacher MJ, Miklowitz DJ, et al. Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study. J Clin Psychiatry 2010 Mar;71 (3): 296-303
21. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl 2009 Nov;52: S13-9
22. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry Suppl 2009 Nov;52: S20-8
23. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011 Apr;127 (1-3): 83-92
24. Brnabic AJ, Kelin K, Ascher-Svanum H, et al. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study. Int J Clin Pract 2011 Sep;65 (9): 945-53
25. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006 Dec;11 (12 Suppl. 14): 1-7
26. McEvoy JP. Risks versus benefits of different types of longacting injectable antipsychotics. J Clin Psychiatry 2006;67 Suppl. 5: 15-8 (Pubitemid 43837697)
27. Naylor GJ, Scott CR. Depot injections for affective disorders. Br J Psychiatry 1980 Jan;136: 105
28. Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981 Sep;64 (3): 226-37 (Pubitemid 11026617)
29. Lowe MR. Treatment of rapid cycling affective illness. Br J Psychiatry 1985 May;146: 558
30. Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986 Jul;1 Suppl. 1: 53-62
31. Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986 Jun;148: 723-5 (Pubitemid 16056798)
32. White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993;8 (2): 119-22 (Pubitemid 23188706)
33. Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar affective disorder. Br J Psychiatry 1994 Dec;165 (6): 827-9 (Pubitemid 24361825)
34. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006 Oct;26 (5): 530-1 (Pubitemid 44401480)
35. Han C, Lee MS, Pae CU, et al. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug;31 (6): 1219-23 (Pubitemid 47081306)
36. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand Suppl 2007;(434): 50-6 (Pubitemid 47231068)
37. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: a 2-year study of 10 patients. Int Clin Psychopharmacol 2008 Mar;23 (2): 88-94 (Pubitemid 351317281)
38. Braunig P, Sacchetti E, Medori R. Risperidone long-acting injectable for maintenance therapy in bipolar disorder: an open-label pilot study. Int J Psychiatr Clin Pract 2008;12 (1): 74-7 (Pubitemid 351878191)
39. Benabarre A, Castro P, Sächez-Moreno J, et al. Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder. Actas Esp Psiquiatr 2009 May-Jun;37 (3): 143-7
40. Vieta E, Nieto E, Autet A, et al. A long-term prospective study on the outcome of bipolar patients treated with longacting injectable risperidone. World J Biol Psychiatry 2008;9 (3): 219-24
41. Fu-I L, Boarati MA, Stravogiannis A, et al. Use of risperidone long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: a case series. J Clin Psychiatry 2009 Apr;70 (4): 604-6
42. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009 Dec;11 (8): 827-39
43. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010 Jul 15;68 (2): 156-62